Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Katja Spiess
Laboratory for Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Science, University of Copenhagen, Denmark, Europe
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
John S Burg
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Jessica R Ingram
Department of Cancer Immunology and Virology, Dana Farber Cancer Institute, Boston, United States
Deepa Waghray
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States
Gertrud M Hjorto
Laboratory for Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Science, University of Copenhagen, Denmark, Europe
Laboratory for Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Science, University of Copenhagen, Denmark, Europe
Hidde L Ploegh
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, United States
Mette M Rosenkilde
Laboratory for Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Science, University of Copenhagen, Denmark, Europe
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States; Department of Structural Biology, Stanford University School of Medicine, Stanford, United States; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, United States
Human cytomegalovirus has hijacked and evolved a human G-protein-coupled receptor into US28, which functions as a promiscuous chemokine 'sink’ to facilitate evasion of host immune responses. To probe the molecular basis of US28’s unique ligand cross-reactivity, we deep-sequenced CX3CL1 chemokine libraries selected on ‘molecular casts’ of the US28 active-state and find that US28 can engage thousands of distinct chemokine sequences, many of which elicit diverse signaling outcomes. The structure of a G-protein-biased CX3CL1-variant in complex with US28 revealed an entirely unique chemokine amino terminal peptide conformation and remodeled constellation of receptor-ligand interactions. Receptor signaling, however, is remarkably robust to mutational disruption of these interactions. Thus, US28 accommodates and functionally discriminates amongst highly degenerate chemokine sequences by sensing the steric bulk of the ligands, which distort both receptor extracellular loops and the walls of the ligand binding pocket to varying degrees, rather than requiring sequence-specific bonding chemistries for recognition and signaling.